A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma
Clinical trial NCT03548207 · COMPLETED
Trial details
- NCT number
- NCT03548207
- Sponsor
- Janssen Research & Development, LLC
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-06-29
- Primary completion
- 2022-08-23
- Enrollment
- 126
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.